Hikma Secures US Rights To Novugen’s Generic Trametinib
Mekinist Rival Set To Have 180-Day Exclusivity On The US Market Post-Launch
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.